CIBC Asset Management
TNXP icon

CIBC Asset Management’s Tonix Pharmaceuticals TNXP Stock Holding History

CIBC Asset Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,568
Closed -$424K – 1426
2025
Q3 		$424K Hold
17,568
– – ﹤0.01% 810
2025
Q2 		$632K Hold
17,568
– – ﹤0.01% 724
2025
Q1 		$314K Buy
+17,568
New +$356K ﹤0.01% 851
2021
Q3 		– Hold
0
– -$14K – 1496
2021
Q2 		– Hold
0
– – – 1362
2021
Q1 		– Hold
0
– – – 1327

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

CIBC Asset Management's TNXP Position: Q4 2025 in Review

CIBC Asset Management sold out of Tonix Pharmaceuticals (TNXP) in Q4 2025, closing a stake of 17,568 shares — an estimated $424K sold.

CIBC Asset Management first reported a position in TNXP in Q1 2025 and held it in 3 quarters. The position peaked at $632K in Q2 2025. 70 funds tracked by Wall St. Rank hold TNXP as of Q4 2025.

  • CIBC Asset Management reported no remaining Tonix Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • CIBC Asset Management sold 17,568 Tonix Pharmaceuticals shares in Q4 2025, an estimated $424K.
  • CIBC Asset Management first reported a position in Tonix Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • CIBC Asset Management's Tonix Pharmaceuticals position peaked at $632K in Q2 2025.
  • 70 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q4 2025.

Based on CIBC Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.